You are here

Genentech

Genentech’s Phase III Trial Yields Positive Results and Hope for Patients with Wet AMD

Genentech’s Phase III Trial Yields Positive Results and Hope for Patients with Wet AMD

BioSpace

clinical trials

wet age-related macular degeneration

Flag link:

Genentech posts long-term data on near-approval Soliris rival

Genentech posts long-term data on near-approval Soliris rival

Fierce Biotech

Flag link:

3 Roche Companies Hope to Make Clinical Trials More Efficient

3 Roche Companies Hope to Make Clinical Trials More Efficient

Medical Devices and Diagnostics Industry

Flatiron Health

Foundation Medicine

clinical trials

Flag link:

FDA approves Genentech’s Tecentriq as first-line monotherapy for certain people with metastatic NSCLC

FDA approves Genentech’s Tecentriq as first-line monotherapy for certain people with metastatic NSCLC

Pharmaceutical Business Review

metastatic non-small cell lung cancer

Flag link:

Genentech lures Regev from Broad Institute to lead research and early development

Genentech lures Regev from Broad Institute to lead research and early development

Fierce Biotech

Broad Institute

Flag link:

Genentech, Novo Nordisk and AbbVie top the list of best workplaces in biopharma

Genentech, Novo Nordisk and AbbVie top the list of best workplaces in biopharma

Fierce Pharma

Flag link:

Experts float Roche stroke drug Activase as potential COVID-19 therapy

Experts float Roche stroke drug Activase as potential COVID-19 therapy

Fierce Pharma

Flag link:

Roche Tests Arthritis Drug Actemra for COVID-19 Pneumonia

Roche Tests Arthritis Drug Actemra for COVID-19 Pneumonia

Motley Fool

clinical trials

Flag link:

Genentech's Esbriet Granted Breakthrough Therapy Designation for uILD

Genentech's Esbriet Granted Breakthrough Therapy Designation for uILD

BioSpace

breakthrough therapy

Flag link:

Genentech pays Bicycle $30M upfront to form discovery-stage immuno-oncology pact

Genentech pays Bicycle $30M upfront to form discovery-stage immuno-oncology pact

Fierce Biotech

Bicycle Therapeutics

immuno-oncology

Flag link:

If biotech had a Mount Rushmore, whose heads would you chisel in the granite?

If biotech had a Mount Rushmore, whose heads would you chisel in the granite?

Stat

Vertex Pharmaceuticals

George Rathmann

Flag link:

Roche's Tecentriq fails trial in form of urothelial cancer

Roche's Tecentriq fails trial in form of urothelial cancer

Reuters

clinical trials

urothelial cancer

Flag link:

Who are the 10 Most Innovative Biopharma Companies?

Who are the 10 Most Innovative Biopharma Companies?

BioSpace

Flag link:

Arcus and Roche Partner on Colorectal and Pancreatic Cancer Trials

Arcus and Roche Partner on Colorectal and Pancreatic Cancer Trials

BioSpace

Arcus Biosciences

clinical trials

colorectal cancer

pancreatic cancer

Flag link:

Roche's flu med Xofluza drives drug resistance and may be a bad choice for kids, study says

Roche's flu med Xofluza drives drug resistance and may be a bad choice for kids, study says

Fierce Pharma

Flag link:

Bay Area Life Sciences Professionals Weigh In on Their Ideal Employers

Bay Area Life Sciences Professionals Weigh In on Their Ideal Employers

BioSpace

Gilead Sciences

Flag link:

Employees’ Perception vs. Employers’ Reality! New Research Shows the Top 3 Areas of Opportunity

Employees’ Perception vs. Employers’ Reality! New Research Shows the Top 3 Areas of Opportunity

BioSpace

Flag link:

After more than a year, Gilead finds new chief medical officer

After more than a year, Gilead finds new chief medical officer

Biopharma Dive

Gilead Sciences

Flag link:

Roche AI Program Can Predict Progression of Diabetic Retinopathy

Roche AI Program Can Predict Progression of Diabetic Retinopathy

BioSpace

artificial intelligence

diabetic retinopathy

Flag link:

Can Synthetic Biology Make Insulin Faster, Better and Cheaper?

Can Synthetic Biology Make Insulin Faster, Better and Cheaper?

Forbes

Flag link:

Pages